A delayed-release composition composed of a Lactobacillus bacterium, Bifidobacterium longum, Streptococcus thermophlus, inulin and xylooligosaccharide is provided for use in reducing nitrogenous waste products in the blood and treating renal failure.

The disclosure discloses Bifidobacterium longum with the ability to relieve atopic dermatitis and its application, and belongs to the technical fields of microorganisms and medicine. The Bifidobacterium longum of the disclosure has the effects of relieving atopic dermatitis, and the effects are specifically embodied in: (1) significantly improving the degree of ear swelling in mice with atopic dermatitis; (2) significantly improving skin pathological symptoms and inflammatory cell infiltration in mice with atopic dermatitis; (3) significantly reducing the serum IgE level in mice with atopic dermatitis; (4) significantly reducing the levels of IL-4 and IL-13 in the skin tissues of mice with atopic dermatitis; and (5) significantly reducing the level of histamine in the skin tissues of mice with atopic dermatitis. Therefore, the Bifidobacterium longum has great application prospects in the preparation of products for the prevention and/or treatment of atopic dermatitis.

The present invention relates to a composition comprising at least one human milk oligosaccharide and/or a precursor thereof, for use in preventing and/or treating necrotizing enterocolitis in infants or young children born by C-section.

Provided are beneficial bacteria that can be beneficially applied across a wide range of age groups and a composition containing the same. Bifidobacterium longum subspecies longum NITE BP-02564 and/or Bifidobacterium longum subspecies longum NITE BP-02565; bacteria classified as Bifidobacterium longum subspecies longum, having utilization ability for sialic acid; and a composition containing the bacteria are also provided. More preferably, a composition containing sialic acid is also provided. More preferably, a composition containing at least one carbohydrate selected from the group consisting of arabinoxylan, arabinan, pectic galactan, and oligosaccharides derived therefrom or containing at least a carbohydrate derived from a gramineous plant or a carbohydrate derived from a solanaceous plant are also provided.

Provided are beneficial bacteria that can be beneficially applied across a wide range of age groups and a composition containing the same. Bifidobacterium longum subspecies longum NITE BP-02564 and/or Bifidobacterium longum subspecies longum NITE BP-02565; bacteria classified as Bifidobacterium longum subspecies longum, having utilization ability for sialic acid; and a composition containing the bacteria are also provided. More preferably, a composition containing sialic acid is also provided. More preferably, a composition containing at least one carbohydrate selected from the group consisting of arabinoxylan, arabinan, pectic galactan, and oligosaccharides derived therefrom or containing at least a carbohydrate derived from a gramineous plant or a carbohydrate derived from a solanaceous plant are also provided.

An isolated lactic acid bacteria strain: Bifidobacterium longum subsp. longum OLP-01 strain for increasing exercise performance and ameliorating fatigue is disclosed. A variety of animal experiments have proved that OLP-01 not only effectively improves muscle strength and swimming endurance but also significantly reduces fatigue-related biochemical indicators, including blood lactate, blood urea nitrogen and the activity of creatine kinase.

An isolated lactic acid bacteria strain: Bifidobacterium longum subsp. longum OLP-01 strain for increasing exercise performance and ameliorating fatigue is disclosed. A variety of animal experiments have proved that OLP-01 not only effectively improves muscle strength and swimming endurance but also significantly reduces fatigue-related biochemical indicators, including blood lactate, blood urea nitrogen and the activity of creatine kinase.

Disclosed herein is a method for alleviating an inflammation-related disorder, which includes administering to a subject in need thereof a composition containing a culture of at least one lactic acid bacterial strain. The at least one lactic acid bacterial strain is selected from the group consisting of Lactobacillus plantarum LPL28 which is deposited at the China General Microbiological Culture Collection Center (CGMCC) under an accession number CGMCC 17954, Bifidobacterium animalis subsp. lactis CP-9 which is deposited at the China Center for Type Culture Collection (CCTCC) under an accession number CCTCC M 2014588, and Bifidobacterium longum subsp. longum OLP-01 which is deposited at the CGMCC under an accession number CGMCC 17345.

The invention discloses a composition comprising LNT and at least another human milk oligosaccharide or precursor thereof, for use in preventing and/or treating necrotizing enterocolitis in infants and young children.

Disclosed are a novel Bifidobacterium longum RAPO (Accession No.: KCTC 13773BP) and a composition for alleviating, treating or preventing rheumatoid arthritis containing Bifidobacterium longum RAPO (Accession No.: KCTC 13773BP) selected herein.